|
Drug maker Indivior PLC will withdraw its shares from trading on the London Stock Exchange in July, the company confirmed on Monday, as it doubles down on its US shareholder base and Nasdaq listing. The Slough-registered but Richmond,Virginia-headquartered pharmaceutical firm, which develops treatments for opioid use disorder, said its final day of trading in London will be Thursday, July 24, with the delisting becoming effective the following day. Its shares will continue to trade on Nasdaq, where the company already has its primary listing, having moved it from London in June last year. Indivior said the decision to delist from London reflects its increasingly US-focused operations, with over 80% of revenue now generated stateside and about 75% of trading volume occurring on Nasdaq. It cited cost savings and administrative simplification as key motivations behind the move. ‘A single primary listing on Nasdaq best reflects the profile of Indivior’s business,’ said Chair David Wheadon. ‘We appreciate the support received from shareholders...and look forward to capitalising on the expected benefits of this move.’ The firm said the London delisting will not impact shareholders who already hold Indivior shares directly or through US brokers. However, holders of UK depositary interests or shares through nominee schemes need to take action ahead of the delisting date to ensure continued trading access via Nasdaq. The decision comes amid wider concerns over the shrinking pool of listings on the London Stock Exchange. According to EY, 2024 saw 88 companies delist or shift their primary listings away from the LSE - the highest number since 2009. Only 18 new listings joined the main market during the year. Still, the exchange scored a small win on Monday as Valterra Platinum Ltd, the spun-off platinum unit of Anglo American PLC, debuted in London with a secondary listing, while maintaining its primary presence on the Johannesburg Stock Exchange. Indivior shares in London were marginally lower at 944.00 pence, giving the company a market capitalisation of £1.18 billion. New York-listed shares were down 0.6% at $12.78 in pre-market trading. Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
